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Treating dementia: will the NICE guidance 2006
change our clinical practice?
Dementia is increasingly becoming a target ofmajor attention
and concern not only for clinicians but also for society and
political policymakers. Its devastating individual, familial and
social impacts, together with the expected rise in prevalence
in the next few years, will challenge the limited resources of
health care systems in Western societies [1]. In the absence
of short term curative treatment(s), more investment and
reorganisation of both health and care services is mandatory
to support both the rapidly increasing number of dementia
sufferers and their carers. Although members of the medical
profession engaged in the treatment of elderly people with
dementia (e.g. old age psychiatrists, geriatricians, neurologists
and general practitioners) are committed to this effort
by ensuring that patients are appropriately assessed and
provided with the best treatment available at the moment,
they must deal with far from ideal conditions to accomplish
this purpose. Recently the Joint Committee on Human
Rights found serious problems in the care of elderly people
in the United Kingdom [2]. Also, as stated by the National
Audit Report [3], until now dementia has not been given the
necessary priority by policy makers. In this context, update
of the National Institute for Health and Clinical Excellence
(NICE) guidelines for dementia in November 2006 [4] and
the recent judicial review on 10 August 2007 imposing
restrictions on prescription of cholinesterase inhibitors
(ChEI) has caused even more apprehension not only to
dementia sufferers and their carers but also to those already
facing numerous constraints when trying to provide the best
care to this vulnerable population.
There is widespread consensus about the necessity to
reconcile individual needs of patients with the limited
resources of theNHS, especially for high-priced technologies
or medications which could easily result in escalating costs.
There is no doubt that the process of clinical decision must
be grounded on the best available scientific information
at the moment. However, controversy arises when the
new paradigm of ‘evidence-based medicine’ is seen as
an instrument to address economic issues through direct
interference in clinical decisions. One of the questions
arising following dialogue between pharmaco-economics
and clinical medicine is whether and to what extent the
economic perspective should be integrated into the clinical
decision-making process. How can this be done without
challenging the norms of good practice by which clinicians
must prioritise their patients’ care, ensuring that they receive
the best possible treatment for their condition?
The NICE guidelines are a major contribution to the
summary and systematisation of all available information
about pharmacological and non-pharmacological manage-
ment of cognitive and behavioural symptoms in dementia.
However, we must not overlook that by using a probabilis-
tic and inductive model, the methodology underlying the
NICE recommendations has great limitations when applied
to individual cases in a routine clinical setting. Indeed, it
could be imprudent to use a rigid standardised approach in
clinical medicine where the complexity and variety of cases
require a thorough approach to identify all possible factors
in the specific pathological process (Figure 1). For example,
the diagnosis of dementia in an individual patient is rarely
straightforward. After a clinical and imaging assessment it
becomes apparent that different types of comorbidity and
pathology exist simultaneously, and the clinical decisionmust
be made judiciously to establish the predominant pathology
contributing to the dementia syndrome.
Another problem is whether the passive application
of these guidelines will become a substitute for clinical
decision rather than acting as a useful instrument in
the clinical decision-making process. By automatically and
rigidly following a flow-chart based on the mini mental
state examination (MMSE) score, the clinician would miss
the complexity involved in making a therapeutic decision,
deferring to the guidelines with ominous consequences
(Appendix 1, available online). If this were the case, despite
the false idea of security that would prevail, errors, waste
of resources and ultimately serious consequences to patients
would certainly result. One of the NICE statements advises
‘health care professionals should not rely on MMSE score
in certain circumstances’. We wonder if they should rely on
MMSE score alone in any circumstance. Indeed, just one item
(concentration and attention question) on this scale can give
a variability in the score of up to 4 points [5]. Furthermore,
in clinical practice, variability of the overall MMSE score can
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Figure 1. Dementia: risk factors and pathogenesis.
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range up to 14 points in the elderly with a varying degree of
poly-comorbidity as well as cognitive impairment (EBM-L,
unpublished). This highlights the importance of a working
operational MMSE framework, which will provide us with
the necessary flexibility, being incorporated within the NICE
guidance.
The changes to NICE guidance also highlight another
important issue. They have confirmed what was already
known: the available drugs represent only modest help for
people with dementia. More than 40% of people with
dementia, irrespective of whether they are treated with
ChEI or not, will face the need for 24-h care during
the first 3 years of their disease course, and over 60% of
them will suffer from malnutrition and consequent further
deterioration in cognitive impairment. This illustrates how
far we, as clinicians, are from a clear understanding of the
pathophysiology of Alzheimer’s disease and other forms of
dementia.
The changes raise many questions, including the issue of
whether we use available anti-dementia drugs appropriately
in line with what is already known about their neuro-
biochemical characteristics. Are some of the ChEI in current
use better in treating distinct forms/variants of Alzheimer’s
disease than others? Why should we be using ChEI only
for moderate dementia, when there is evidence that they
are also effective (and in some instances result in even
better response) in severe dementia? What about postponing
cognitive decline in mild dementia? Why should we limit
the use of Memantine, and not use it in accordance with
its pharmacological properties which indicate its suitability
for treatment of mild dementia? What are the clinical
implications of the latest molecular pathological and neuro-
biochemical research in dementia? What do unchanged
levels of CSF tau and beta amyloid protein following
ChEI treatment tell us about the neurobiological impact of
these drugs on the disease process [6]? How about depleted
amyloid levels in brain tissue of Alzheimer’s disease patients
following ChEI treatment [7]?
These are only a few of the questions arising from our
routine daily clinical practice. There is also significant data
from laboratory research into dementia which should not
be restricted solely to an academic setting. The combination
of clinical and research findings and their influence on
therapeutic approach(es) to dementia can only be useful
when fostered more closely. It is the responsibility not only
of the scientific community but also of society in general,
to put more effort into research to develop novel and more
efficient drugs to modify and cure the dementia disease
process.
In conclusion, NICE guidelines about the therapeutic
management of cognitive symptoms of dementia are
welcome as an important instrument serving health
professionals. However, many memory specialists directly
involved in the clinical care of dementia sufferers do not
feel that these guidelines will largely influence our clinical
practice. This was confirmed recently at the Memory Clinic
Conference held in Newcastle (29 June 2007) when about
40% of the memory specialists agreed on the latter. Although
over 80% of us agree on the need for ChEI to be used in
mild dementia [8], we still lack data about how many of us
are using them for this condition, and how beneficial they
are in a routine clinical setting. The guidelines should not be
erroneously overvalued and promoted as a ‘miracle’ strategy
to decrease costs and to improve the quality of clinical
practice. These two objectives can be achieved only with
sound investment in clinical training and the development
of solid clinical and communication skills and competent
clinical judgement. Using the guidelines as a substitute for
these will surely frustrate both the economic objectives and
the patients’ expectations.
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